Tag:

Bayer

Latest Headlines

Latest Headlines

NICE sings a different tune for Bayer's prostate cancer drug Xofigo

Bayer has had a tough time winning approval from U.K. cost-effectiveness gatekeepers for its prostate cancer therapy Xofigo. Now, the company is celebrating a bright point for Xofigo as NICE changed its tune and backed the drug for certain patients.

Eyeing Xofigo growth, Bayer launches 'speak up' campaign in prostate cancer

New survey data show that 68% of men--nearly 7 in 10--sometimes ignore the symptoms of prostate cancer, putting off treatment for advanced forms of the disease. For Bayer--which markets cancer drug Xofigo to treat metastatic castration-resistant prostate cancer--that's far too many.

Roche, Novartis and Bayer snag NICE OKs

The U.K.'s cost-effectiveness gatekeeper, the National Institute for Health and Care Excellence (NICE), has bestowed its favor on a crop of new drugs, granting nods to contenders from Roche, Novartis and Bayer.

Bayer CEO Dekkers looking 'with interest' at animal-health additions

Bayer may be looking at a potential cash infusion, as it prepares to divest its MaterialScience unit and likely take it public by mid-2016. Bayer just might use that cash to make an acquisition in animal health.

Bayer chief may plow spinoff cash into animal health buys

Bayer has seen many an M&A opportunity come and go when it comes to bolstering its animal health unit. But once it jettisons its plastics unit--a move that could generate some extra dough--it might finally be ready to strike a deal.

Bayer set to spend $3.4M this year to expand its Indonesian operations

German pharmaceutical giant Bayer said it expects to spend $3.4 million to expand its Indonesian production capacity for effervescents this year.

As Bayer preps for its slim-down, a restructuring looms--but jobs are safe, CEO says

As Bayer moves closer to hiving off its plastics businesses and becoming a life sciences-focused company, a restructuring is afoot, the company said Wednesday. But it's one that won't cost the drugmaker any staff positions.

England's Cancer Drugs Fund keeps Bayer's Stivarga, axes Eisai and Lilly meds

England's Cancer Drugs Fund has drawn a hard line when it comes to its list of covered meds, axing cancer treatments despite pushback from drugmakers. But Bayer scored a victory for its cancer med Stivarga, getting the fund to reverse its decision and keep the drug on its list even as rival companies lose similar battles.

Sinocare said to bid $1B for Bayer diabetes devices, piping Panasonic

China's Sinocare reportedly has made a $1 billion bid for Germany-based Bayer's diabetes devices. As maker of blood-sugar monitors, Sinocare would be challenging a broader based company, Panasonic Healthcare, already months into discussions with the seller.

China's Sinocare interested in buying Bayer diabetes device unit

Chinese bidders are emerging in the long-sought sale of Bayer's diabetes device business, as the German giant seeks to focus on its core pharmaceutical interests.